title: Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats.
abstract: OBJECTIVE
  The aim of this study was to investigate omega-3 fatty acids (FAs) treatment of experimental steatosis and the consequent effect on ischemia-reperfusion (IR) injury.
  
  
  BACKGROUND
  Fatty livers are more susceptible to IR injury and display decreased regenerative capacity. Consequently, restrictions exist for patients with fatty livers to undergo a major hepatectomy or to participate in living donor liver transplantation. Until recently, weight reduction constituted the only proven therapy for patients with fatty livers.
  
  
  METHODS
  Steatosis was induced by a 3-wk methionine/choline-deficient diet, followed by oral administration of omega-3 FAs (Omega-3), standard lipid solution (Lipid), or NaCl (Saline) during 2 wk. Control animals received a standard diet without treatment. Rats underwent partial (70%) hepatic IR combined with partial hepatectomy (PHx) of the non-ischemic lobes (30%) followed by 24-h reperfusion.
  
  
  RESULTS
  Histological analysis revealed mild (5-33%) macrovesicular steatosis in omega-3-treated animals vs. severe (>66%) macrovesicular steatosis in both Lipid and Saline groups. Following IR/PHx, omega-3-treated rats exhibited reduced serum ALT levels after 6- and 24-h reperfusion, a reduced hepatic TNF-α content, and an improved anti-oxidative capacity.
  
  
  CONCLUSIONS
  Omega-3 treatment significantly reduces experimental hepatic steatosis and associated pathophysiological features, resulting in significantly reduced IR injury following PHx.
authors.affiliation: Department of Surgery (Surgical Laboratory), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Hendrik A
authors.initials: HA
authors.lastname: Marsman
authors.forename: Michal
authors.initials: M
authors.lastname: Heger
authors.forename: Jaap J
authors.initials: JJ
authors.lastname: Kloek
authors.forename: Syert L
authors.initials: SL
authors.lastname: Nienhuis
authors.forename: Fiebo J W
authors.initials: FJ
authors.lastname: ten Kate
authors.forename: Thomas M
authors.initials: TM
authors.lastname: van Gulik
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000704:Analysis of Variance; D000818:Animals; D002796:Choline Deficiency; D019587:Dietary Supplements; D005229:Fatty Acids, Monounsaturated / Q000032:analysis; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology / Q000627:therapeutic use*; D005234:Fatty Liver / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006498:Hepatectomy; D008099:Liver / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D008297:Male; D008715:Methionine / Q000172:deficiency; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000473:pathology* / Q000503:physiopathology* / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D005229:Fatty Acids, Monounsaturated; D015525:Fatty Acids, Omega-3; D014409:Tumor Necrosis Factor-alpha; D008715:Methionine; D000410:Alanine Transaminase